



acetyltransferase genes in B-cell
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B-cell non-Hodgkin’s lymphoma comprises biologically and clinically distinct diseases the pathogenesis of which is
associated with genetic lesions affecting oncogenes and tumour-suppressor genes. We report here that the two most
common types—follicular lymphoma and diffuse large B-cell lymphoma—harbour frequent structural alterations
inactivating CREBBP and, more rarely, EP300, two highly related histone and non-histone acetyltransferases (HATs)
that act as transcriptional co-activators in multiple signalling pathways. Overall, about 39% of diffuse large B-cell
lymphoma and 41% of follicular lymphoma cases display genomic deletions and/or somatic mutations that remove or
inactivate the HAT coding domain of these two genes. These lesions usually affect one allele, suggesting that reduction in
HAT dosage is important for lymphomagenesis. We demonstrate specific defects in acetylation-mediated inactivation of
the BCL6 oncoprotein and activation of the p53 tumour suppressor. These results identify CREBBP/EP300mutations as a
major pathogeneticmechanism shared by common forms of B-cell non-Hodgkin’s lymphoma, with direct implications
for the use of drugs targeting acetylation/deacetylation mechanisms.
Diffuse large B-cell lymphoma (DLBCL) represents the most com-
mon form of B-cell non-Hodgkin lymphoma (B-NHL), accounting
for about 30% of new diagnoses and also arising as a frequent clinical
evolution of follicular lymphoma1. The molecular pathogenesis of
DLBCL is associated with multiple genetic lesions that segregate in
part with individual phenotypic subtypes, namely germinal-centre
B-cell-like (GCB) and activated B-cell-like (ABC) DLBCL, suggesting
the involvement of distinct oncogenic pathways2–8. However, the full
spectrum of lesions that contribute to malignant transformation
remains unknown. Genome-wide efforts toward the identification
and functional characterization of the entire set of structural altera-
tions present in the DLBCL genome are required for a complete
understanding of its pathogenesis9.
Towards this end, we have integrated next-generation whole-
exome sequencing analysis of seven DLBCL cases and genome-wide
high-density single nucleotide polymorphism (SNP) array analysis of
72 DLBCL cases. This combined approach led to the identification of
over 450 loci that are affected by somatic point mutations and/or by
recurrent, focal gene copy number aberrations. Among those that
have been independently validated, the most commonly involved
regions were those harbouring the acetyltransferase genes CREBBP
(CBP) and EP300 (p300). CREBBP encodes a highly conserved and
ubiquitously expressed nuclear phosphoprotein that, together with
the closely related protein EP300, belongs to the KAT3 family of
histone/protein lysine acetyltransferases10,11. CREBBP and EP300
function as transcriptional coactivators for a large number of DNA-
binding transcription factors involved in multiple signalling and
developmental pathways, by modifying lysine residues on both his-
tone and non-histone nuclear proteins12,13.
CREBBP and EP300 enhance transcription by multiple mechan-
isms, including: (1) targeted acetylation of chromatin12,13; (2) acetyla-
tion of transcriptional activators (such as the tumour suppressors p53
and GATA1)14–17; and (3) acetylation-mediated inactivation of tran-
scriptional repressors (such as the DLBCL-associated oncogene
BCL6)18. Additionally, bothmolecules were found to exhibit ubiquitin
ligase activity19,20. Consistent with the involvement in critical cellular
functions, homozygous null mice for either Crebbp or Ep300 are early
embryonic lethal21,22, and the same is true for compound Crebbp/
Ep300 double heterozygous mice21,22. Haploinsufficiency of CREBBP
(and, rarely, EP300) is responsible for Rubinstein–Taybi syndrome,
an autosomal congenital disorder characterized bymental and growth
retardation, skeletal abnormalities and predisposition to tumour
development23–25. Somatic mutations of these two genes are exceed-
ingly rare in epithelial cancers26–28, and only three cases were reported
to carry EP300, but not CREBBP mutations in haematologic malig-
nancies29,30. Additionally, chromosomal translocations of CREBBP
are associated with an infrequent type of acute myeloid leukaemia
and with therapy-related acute myeloid leukaemia andmyelodysplas-
tic syndrome, although the precise consequences of these lesions have
not been fully elucidated31–33.
Monoallelic lesions of CREBBP in DLBCL
Following initial observations from whole-exome sequencing analysis
of sevenDLBCLcases and pairednormalDNAs,weperformed targeted
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re-sequencing of the entire CREBBP coding exons in 134 DLBCL
samples representative of major phenotypic subtypes. This analysis
revealed a total of 34 sequence variants distributed over 30 samples
and the somatic origin of which was documented by analysis of paired
normal DNAs (available in eight cases)(Fig. 1a and b, and Supplemen-
tary Table 1). Of these variants, 17 (50%) were inactivating events,
including nonsense mutations (n5 9), frameshift insertions/deletions
(n5 7) and mutations at consensus splice donor/splice acceptor sites
(n5 1), which generate aberrant transcripts carrying premature stop
codons. On the basis of their distribution along the CREBBP protein,
these mutations are all predicted to cause the elimination or truncation
of the HAT domain (Fig. 1a and Supplementary Table 1). The remain-
ing variants included three in-frame deletions and 14 missense muta-
tions, primarily within the HAT domain (Fig. 1a and Supplementary
Table 1), suggesting that they may be functionally important (see
below). Although CREBBP mutations were identified in both DLBCL
phenotypic subtypes, their frequency was significantly higher in GCB-
DLBCL, where they account for about 32% of the cases (n5 21/65)
as compared to 13% in ABC/non-classified (NC) DLBCL (n5 9/69;
P, 0.01) (Fig. 1c).
High-density SNP array analysis, available for 72 samples from the
same panel, and fluorescence in situ hybridization (FISH) analysis
revealed the presence of monoallelic deletions encompassing or
internal to the CREBBP locus in eight additional cases (five GCB-
DLBCL and three ABC/non-GC-DLBCL), and a homozygous dele-
tion in one patient (Fig. 2a and b, and Supplementary Fig. 1). Notably,
the loss of genetic material was smaller than 240 kilobases (kb) in four
cases and, in two patients (2147 and 2043), involved only a limited
subset of CREBBP exons, thereby identifying this gene as the specific
target (Fig. 2a and Supplementary Table 2). In two additional samples
for which copy number data were not available, direct sequencing
analysis revealed a hemizygous missense mutation, reflecting either
the loss of the second allele or copy neutral loss of heterozygosity
(Supplementary Table 1). When combining the sequencing data with
the copy number data, CREBBP mutations and deletions were found
to be mutually exclusive in most samples, revealing a predominantly
monoallelic distribution (n5 33/39 cases) (Fig. 2c). Rare instances of
biallelic genetic lesions include the homozygous loss, a missense
mutation with loss of heterozygosity (two primary biopsies), biallelic
nucleotide substitutions (two cases), and a frameshift deletion with
missense mutation of the second allele in the OCI-Ly8 cell line. Thus,
29% of all DLBCL patients (n5 39/134), corresponding to 41.5% of
GCB-DLBCL and 17% of ABC-DLBCL, harbour genomic alterations
affecting the CREBBP gene (Fig. 2d).
Frequent mutations of CREBBP in follicular lymphoma
Wenext analysed various types ofmature B-NHL, including follicular
lymphoma, Burkitt lymphoma, marginal-zone lymphoma and
chronic lymphocytic leukaemia. Mutations analogous to those found
in DLBCL were frequent in follicular lymphoma (32.6%, with 16
events distributed over 15/46 cases), but not in other lymphoma types,
suggesting a specific role in the pathogenesis of these two diseases
(Supplementary Fig. 2). This analysis also revealed the existence of
several mutational hotspots at specific codons within the HAT
domain, including R1446 (also mutated in B-cell acute lymphoblastic
leukaemia34), Y1503 and D1435; in addition, a 3-base-pair (bp) in-
frame deletion causing the loss of S1680 was observed in five cases,
suggesting a functional role for this currently uncharacterized serine
(Supplementary Table 1). None of these recurrent changes was
detected in paired normal DNA, indicating that they do not represent
germline polymorphisms. Although copy number data were not
available for the same follicular lymphoma panel, array-CGH analysis
performed on a distinct data set showed deletions spanning the
CREBBP locus in only 1/68 cases (not shown). Collectively, these
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Figure 1 | The CREBBP gene is mutated inDLBCL. a, Schematic diagram of
the CREBBP gene (top) and protein (bottom). Exons are colour-coded
according to the corresponding protein functional domains (CH, cysteine-
histidine rich; KIX, CREB-binding; Bromo, bromodomain; HAT, histone
acetyltransferase; Q, polyglutamine stretch). Colour-coded symbols depict
distinct types of mutations. b, Sequencing traces of representative mutated
DLBCL tumour samples and paired normal DNA; arrows point to the position
of the nucleotide change (amino acid change shown at the bottom).
c, Distribution of CREBBP mutations in major DLBCL subtypes; the actual
number of mutated samples over the total analysed is given. NC, not classified.
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EP300mutations in DLBCL and follicular lymphoma
Given the significant structural and functional similarities between
CREBBP and EP300, we investigated whether this second member of
the KAT3 acetyltransferase family is also targeted by structural altera-
tions in B-NHL. Mutational analysis of the same panel identified 19
sequence variants leading to amino acid changes (n5 11), in-frame
deletions (n5 2), and premature stop codons due to frameshift dele-
tions, aberrant splicing or nonsense mutations (n5 6) (Supplemen-
tary Fig. 3a and Supplementary Table 3). These lesions were found in
10%ofDLBCL (n5 13/134) and 8.7% of follicular lymphoma samples
(n5 4/46), but were almost absent in other B-NHLs (Supplementary
Fig. 3b). Seven additional DLBCLs harboured monoallelic deletions
spanning, although not limited to, the EP300 locus (Supplementary
Fig. 3c, Supplementary Table 4 and data not shown). Notably, struc-
tural alterations ofCREBBP andEP300 coexist in only aminority of the
affected cases (n5 6/53 DLBCL and 0/19 follicular lymphoma) (Sup-
plementary Fig. 3d), suggesting that inactivation of these loci is at least
in part functionally equivalent. Thus, overall about 39% of all DLBCL
and at least 41% of follicular lymphoma cases (based on mutations
only) display structural alterations of KAT3 family genes.
CREBBP and EP300 protein expression
To compare the CREBBP and EP300 protein levels in normal and
transformed B cells, and to investigate the expression of the retained
normal allele in cases carrying monoallelic genomic alterations, we
examined the expressionpattern of these twoproteins in reactive human
tonsils and in 78 DLBCL primary cases, of which 49 harboured both
genes in wild-type configuration, using immunofluorescence and
immunohistochemical analysis. Consistent with their reported ubiquit-
ous expression, CREBBP and EP300 were detectable in naive B cells
within the mantle zone and, at higher levels, in germinal-centre B cells
(Fig 3a). Notably,most of themonoallelically deletedDLBCL cases were
positive for the two proteins, although at reduced levels, demonstrating
that the residual wild-type allele is expressed (see Fig. 3b and c for
representative examples). Furthermore, reverse-transcription polymer-
ase chain reaction (RT–PCR) amplification and direct sequencing of the
ten CREBBP-mutated cell lines invariably showed the presence of the
wild-type allele (Supplementary Fig. 4),whilewesternblot analysis using
antibodies directed against the amino-terminal portion of CREBBP
revealed the expression of a full-length protein, corresponding to the
wild-type allele, in most of the cell lines carrying truncating gene muta-
tions, aswell as in themonoallelically deleted SUDHL5cells (Fig. 3d, top
panel). Slightly different findings were observed for EP300, where the
presence of truncating mutations or deletions was associated with the
absence of protein expression in four affected cell lines (Fig. 3d, second
panel from top). With the exception of SUDHL2, both CREBBP and
EP300messenger RNAs were readily detected by northern blot analysis
in all lines analysed (Fig 3d, panels 4 and 5 from top).
Interestingly, a few additional lines were found to express very low
or undetectable protein levels, despite the presence of mRNA and the
absence of structural alterations in the corresponding gene (see
CREBBP in BJAB and SUHDL2, or EP300 in SUDHL7) (Fig. 3d).
Similarly, 6/78 (8%) DLBCL biopsies from patients with intact alleles
appeared to lack expression of the two proteins, either simultaneously
(three cases) or individually (two CREBBP1/EP3002 cases and one
CREBBP2/EP3001 case) (Fig. 3c and e). Thus, the fraction of DLBCL
patients with defective CREBBP and EP300 may be higher than that
determined on the basis of genetic lesions alone, suggesting that
alternative mechanisms of KAT3 gene family inactivation may have
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Figure 2 | Mutations and deletions of CREBBP are predominantly
monoallelic. a, Map of the genomic region encompassing CREBBP and its
neighbouring genes on chromosome16p13.3. Blue lines below themap indicate
the extent of the deletions identified in nine DLBCL samples, with the darker
blue segment corresponding to a homozygous loss. b, dChipSNP heatmap
showing median-smoothed log2 copy number ratio for eight DLBCL biopsies
harbouring CREBBP deletions, and two normal DNAs. A vertical blue bar
indicates the location of the CREBBP locus; in the red-to-blue colour scale,
white corresponds to a normal (diploid) copy number log-ratio, blue
corresponds to deletion and red to gain. c, Allelic (A or B) distribution of
CREBBP genetic lesions in individual DLBCL samples. d, Overall frequency of
CREBBP structural alterations in DLBCL subtypes (mutations and deletions,
combined).
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CREBBPmissense mutants fail to acetylate BCL6 and p53
The presence of gross gene deletions and the distribution of truncating
mutations clearly predict a complete gene inactivation or the loss of
multiple key functional domains, including the HAT; on the contrary,
the functional consequences of the numerousCREBBPmissensemuta-
tions required direct experimental analysis. Notably, of the 30 total
events identified, 27 cluster within HAT coding exons, suggesting a
selective pressure to alter theCREBBP enzymatic activity (Supplemen-
tary Table 1). In particular, 19 mutations were located within a 68-
amino-acid stretch that is 96% identical to EP300 and includes the
contact surface for coenzyme A (CoA)35 (Supplementary Fig. 5). We
therefore examined the effect of these mutations on the ability of
CREBBP to acetylate known physiologic substrates. We selected
BCL6 and p53 because of their biological relevance for germinal-
centre development and lymphomagenesis4,36. In fact, acetylation of
the tumour suppressor p53 is indispensable for its transcriptional
activity14,15,37, whereas EP300-mediated acetylation of the proto-
oncoprotein BCL6 leads to inactivation of its transcriptional repressor
function18.
Transient transfection/co-immunoprecipitation assays confirmed
that, analogous to EP30018, CREBBP binds to and acetylates BCL6,
leading to a dose-dependent impairment in its ability to repress a
BCL6-responsive reporter gene (Supplementary Fig. 6a and b). We
then generated haemagglutinin (HA)-tagged constructs for expres-
sion of nine representative CREBBP alleles harbouring missense
mutations within (n5 6) or immediately outside (n5 2) the core
HAT domain, as well as a premature stop codon (R1360X)
(Fig. 4a). Notably, all of the HAT domain mutant proteins had lost
their ability to acetylate BCL6 (Fig. 4b) and to interfere with its trans-
repression activity, consistent with the reported role of acetylation in
inactivating BCL6 (Fig 4c). Conversely, no significant effects were
observed from the C1240R and K1320R proteins or from two addi-
tional alleles (P1053L, Q1079H) harbouring mutations outside the
HAT domain (Supplementary Table 1 and data not shown), although
C1240R appeared to have lost its activity in the reporter assay, sug-
gesting that alternative mechanisms may be involved.
When tested on the tumour suppressor p53, the same core HAT
mutants were either impaired or severely attenuated (H1487Y and
D1435E) in their acetylation activity, as compared to wild-type
CREBBP or to C1240R and K1320R (Fig. 4d). It should be noted that
C1240R and K1320R represent a second mutational event in cases
carrying an additional truncatingCREBBPmutation (see Supplemen-
tary Table 1), suggesting the possibility that they represent passenger
events or that they confer more subtle functional consequences.
Taken together, these findings demonstrate that CREBBP missense
mutant alleles have been selected for their defective HAT activity. In
particular, the impairment on BCL6 and p53 acetylation is consistent
with specific effects of CREBBP genetic lesions in favouring the con-
stitutive activity of the BCL6 oncogene over the function of the p53
tumour suppressor.
CREBBPmutations reduce affinity foracetyl-CoAbinding
To investigate the mechanisms responsible for the observed loss of
function on BCL6 and p53, we examined the effect of CREBBP muta-
tions on subcellular localization, enzyme–substrate complex formation,
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Figure 3 | CREBBP and EP300 expression in normal and transformed
B-cells. a, Immunofluorescence analysis of reactive tonsils. BCL6 identifies
germinal-centre B cells, and DAPI is used to detect nuclei.
b, c, Immunohistochemistry analysis of CREBBP (b) and EP300 (c) protein
expression in representative DLBCL biopsies (genomic status as indicated, D is
deletion; scale bar, 100mm). Sample 2147, which harbours a homozygous
CREBBP deletion, serves as negative control. d, Western blot (WB) and
northern blot (NB) analysis of DLBCL cell lines carrying wild-type or aberrant
CREBBP and EP300 alleles (colour-coded as indicated). The aberrant band in
SUDHL10 corresponds in size to the predicted ,220-kilodalton (kDa)
CREBBP truncated protein. *Non-specific bands. Tubulin and GAPDH
control for total protein andRNA loading, respectively. e, Overall proportion of
DLBCL biopsies showing defective CREBBP/EP300 function due to genetic
lesions (red scale) and/or lack of protein expression (blue scale).
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the nuclear compartment and could be efficiently co-immunopreci-
pitated with BCL6 or p53 (Supplementary Fig. 7 and data not shown),
indicating that the inability to acetylate these substrates in vivowas not
due to mislocalization or to impaired physical interaction. Instead, in
vitro acetylation assays using recombinant glutathione S-transferase
(GST)–p53andhighlypurified,wild-type ormutatedCREBBPproteins
demonstrated a marked, acetyl-CoA dose-dependent defect in the
enzymatic activity of the core HAT mutants (Fig. 5 and Supplemen-
tary Fig. 8), suggesting that these changes impair the affinity for acetyl-
CoA (see also Supplementary Fig. 5).
CREBBP mutants are biologically inactive
To further investigate the consequences of CREBBP missense muta-
tions on its function as a transcriptional co-activator, we examined the
response of endogenous 39,59-cyclic adenosine monophosphate
(cAMP) response element-binding protein (CREB) target genes in
mouse embryonic fibroblasts (MEFs) carrying conditional Crebbp
and Ep300 double knockout alleles, reconstituted with retroviral vec-
tors expressing either wild-type or DLBCL-associated mutant Crebbp
complementary DNAs (Supplementary Fig. 9a), and treated with
forskolin and IBMX (two inducers of Protein Kinase A activity). In
normal cells, Protein Kinase A-mediated phosphorylation of CREB
is required for the recruitment of CREBBP, which in turn leads to
transcriptional activation of cAMP-responsive genes38. As previously
observed39, quantitativeRT–PCR analysis of CREBBP/EP300-depend-
ent CREB target genes confirmed their upregulation in double-
knockout cells reconstituted with wild-type CREBBP expression
constructs (Supplementary Fig. S9b, column 2 from left). In contrast,
all four DLBCL-derived CREBBP mutants tested were generally
deficient for cAMP-responsive transcription, as was the HAT-dead
control W1502A/Y1503S40 (Supplementary Figs 9b and 10). These
mutants were also associated with reduced endogenous histone
H3K18 acetylation (Supplementary Fig. 11). Finally, we testedwhether
the mutant CREBBP polypeptides were proficient in rescuing the pro-
liferative defect of the double-knockout cells, given that this system
provides a specific readout for the biological activity of theCREBBPpoint
mutants. Notably, cells transduced with the four DLBCL-associated
alleles displayed significantly impaired cell growth compared to wild-
type reconstituted cells, as measured in the yellow fluorescent protein
(YFP) 1 (double-knockout) population (Supplementary Fig. 9c).
Collectively, the data presented above provide direct experimental evid-
ence for a role of HAT missense mutations in impairing the acetyl-
transferase activity of CREBBP and its function as a transcriptional
coactivator.
Discussion
These results indicate that inactivation of CREBBP/EP300 represents
a common event in the two most frequent forms of B-NHL, namely
follicular lymphoma and DLBCL. Previous extensive surveys in
malignancies of epithelial origin have reported inactivatingmutations
of EP300 and CREBBP in exceedingly rare cases (,2% of primary
biopsies)26–28. Considering their almost total absence in solid tumours,
and the finding of recurrent mutations in B-cell acute lymphoblastic
leukaemia34, our results point to a specific role for CREBBP/EP300
inactivation in the pathogenesis of malignancies derived from
B-lymphocytes. Overall, CREBBP/EP300 lesions are among the most
frequent structural alterations yet detected in follicular lymphoma and


















































































































































































































Figure 4 | CREBBPmissense mutations impair its ability to acetylate BCL6
and p53. a, Schematic diagram of the CREBBP HAT and CH domains, with
the CREBBP point mutations tested in b–d (in green, residues located
immediately outside the HAT domain). b, Acetylation levels of exogenous
BCL6 in Flag immunoprecipitates obtained fromHEK293T cells co-transfected
with wild-type or mutant CREBBP expression vectors. b-Actin is the input
loading control. IP, immunoprecipitation. c, Luciferase reporter assays using a
synthetic 5X-BCL6 reporter. The bar graph shows results as relative activity
compared to the basal activity of the reporter, set as 1 (mean6 s.d., n5 2). The
gel shows BCL6 and CREBBP-HA protein levels in the same lysates. Note that
the amount of transfected BCL6-encoding and CREBBP-encoding plasmids
was adjusted to achieve equal protein amounts. d, p53 acetylation in HEK293T
cells co-transfected with the indicated CREBBP expression vectors. The anti-
p53 antibody documents comparable amounts of p53 (exogenous 1
endogenous). Green fluorescent protein (GFP) monitors for transfection
efficiency, and b-tubulin is used as the loading control. ‘Long’ indicates long
exposure.
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of these common diseases. Moreover, the observation of significantly
reduced CREBBP and EP300 expression levels in a sizeable fraction of
DLBCL samples, independent of genetic lesions (Fig. 3e and Sup-
plementary Fig. 12), suggests that additional epigenetic mechanisms
may cause reduction of HAT dosage in a larger fraction of tumours.
One key observation of this study is thatCREBBP/EP300 lesions are
mostly detected in heterozygosity, suggesting a haploinsufficent role
in tumour suppression. This notion is supported by several observa-
tions. First, congenital heterozygous mutations ofCREBBP/EP300 are
sufficient to cause significant pathologic and developmental pheno-
types, including tumorigenesis, in patients with Rubinstein–Taybi
syndrome23–25, thereby confirming the deleterious effect of reduced
HAT activity. Second, a fraction of mice with conditional deletion of
Crebbp in mature B cells showed reduced survival past 12 months of
age41. Haematologic malignancies were also reported in 22% of con-
stitutive 10–21-month-old Crebbp heterozygous mice and about 30%
of chimeric animals after bone marrow or spleen cell transplantation
from Crebbp heterozygotes42. Third, in contrast with the abundantly
expressed histone deacetylases, HATs are limiting in the cell, suggest-
ing that small dosage variations can have severe biological conse-
quences43. Overall, these data provide direct evidence that CREBBP
(and, more rarely, EP300) are haploinsufficient tumour suppressors,
the specific roles of which in lymphomagenesis will have to be tested
by conditional deletion of these alleles in germinal-centre B cells.
Given the global involvement of CREBBP/EP300 on gene tran-
scriptional regulation, it is difficult to predict which cellular targets/
pathways may be critically affected by HAT reduction in lymphoma-
genesis. At this stage, our results demonstrate that mutant CREBBP
and EP300 proteins are deficient in acetylating BCL6 and p53, leading
to constitutive activation of the oncoprotein and to decreased p53
tumour suppressor activity. The balance between the activities of these
two genes is critical for the regulation of DNA damage responses in
mature germinal-centre cells during immunoglobulin gene remodel-
ling36,44. Thus, the consequences of BCL6 activity overriding p53 would
be an increased tolerance forDNAdamage in the context of diminished
apoptotic and cell cycle arrest responses.
These results have important therapeutic implications in view of
current attempts to use a variety of histone deacetylase inhibitors as
anti-cancer drugs. Although the benefits of these compounds have
been proved in certain malignancies, such as mature T-cell lympho-
proliferative disorders, their efficacy in other common cancers,
including B-NHL, is uncertain at this stage45. The findings of this
study suggest that the use of histone deacetylase inhibitors has a
rational basis in B-NHL, because it may contribute to re-establishing
physiologic acetylation levels. On the other hand, their efficacy should
be re-evaluated by stratifying patients based on the presence of HAT
defects as well as by testing the numerous histone deacetylase and
sirtuin inhibitors with target specificity.
METHODS SUMMARY
Mutation analysis.The complete coding sequences and exon/intron junctions of
CREBBP and EP300were analysed by PCR amplification and direct sequencing of
whole-genome amplified DNA using the oligonucleotides reported in Sup-
plementary Tables 5 and 6. Mutations were confirmed from both strands on
independent PCR products amplified from genomic DNA, and their somatic
origin was documented by analysis of matched normal DNA in available cases.
SNP array analysis. This was performed using Affymetrix Genome-Wide 6.0
Arrays and a computational workflow, which is described in detail in the
Supplementary Information.
In vivo and in vitro characterization of HAT activity. The ability of CREBBP
mutants to acetylate BCL6 and p53 was assessed in human embryonic kidney
(HEK293T) cells after co-transfection of pCMV–Flag–BCL6 (or pCIN4–Flag–
p53) with plasmids encoding wild-type versusmutantHA-taggedmouse Crebbp.
BCL6 acetylation was evaluated on Flag/M2 immunoprecipitates using antibodies
directed against acetyl lysines; for p53, western blot analysis was performed on
whole-cell extracts using a specific anti-acetylated p53 antibody. The amounts of
exogenousCREBBPweremonitored using anti-HAandanti-CREBBP (A22, Santa
Cruz Biotechnology) antibodies. In vitro acetylation assays were performed using
recombinant GST-p53 and purified CREBBP-HA proteins, in the presence of the
indicated amounts of acetyl-CoA.
Transient transfection/reporter gene assays. The effect of CREBBP on BCL6-
dependent transcription was assessed in HEK293T cells co-transfected with a
luciferase reporter vector containing five BCL6 consensus binding sites upstream
of the SV40 promoter (5XBCL6) and the pCMV–Flag–BCL6 construct, in the
absence or presence of wild-type versus mutant CREBBP–HA expression vectors
(see the online-only Methods).
Reconstitution of Crebbp/Ep300 null MEFs. Crebbp flox/flox;Ep300 flox/flox;YFP1
conditional (double knockout) MEFs have been described39. CREBBP expression
was restored by retroviral infectionwith constructs encoding forHA-taggedwild-
type or mutant Crebbp, and cells were analysed for H3K18 acetylation, cAMP-
dependent transcriptional responses and cell proliferation (see the online-only
Methods).
Full Methods and any associated references are available in the online version of
the paper at www.nature.com/nature.
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Figure 5 | DLBCL-associated mutations in the CREBBP HAT domain
decrease its affinity for acetyl-CoA. a, Western blot analysis of in vitro
acetyltransferase reactions performed using the WT or mutant Y1450C
CREBBP–HA recombinant protein and a GST–p53 substrate in the presence of
decreasing amounts of acetyl-CoA. Anti-HA and anti-p53 antibodies document
the presence of equivalent amounts of effector and substrate proteins in the
reaction. Ac, acetylated. b, In vitro acetyltransferase activity of the indicated
CREBBP–HA mutant proteins in the same assay using 25nM acetyl-CoA.
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METHODS
DNA extraction, amplification and sequencing. Genomic DNA was extracted
by standard methods, and whole-genome amplification was performed using the
RepliG kit (Qiagen) according to the manufacturer’s instructions. Sequences for
all annotated exons and flanking introns of CREBBP and EP300 were obtained
from the UCSC Human Genome database, using the corresponding mRNA
accession number as a reference (NM_004380.2 andNM_001429.3, respectively).
PCR primers, located$50 bp upstream or downstream to target exon boundaries,
were designed in the Primer 3 program (http://frodo.wi.mit.edu/primer3/) and
filtered usingUCSC In Silico PCR (http://genome.ucsc.edu) to exclude pairs yield-
ing more than a single product (Supplementary Tables 5 and 6). Purified ampli-
conswere sequenced directly fromboth strands as described2, and compared to the
corresponding germline sequences, using the Mutation Surveyor Version 2.41
software package (Softgenetics; http://www.softgenetics.
com). Somaticmutations were confirmed on independent PCR products obtained
from high-molecular-weight genomic DNA. Synonymous mutations, previously
reported polymorphisms (Human dbSNP Database at NCBI, Build 130, and
Ensembl Database) and changes present in the matched normal DNA, when
available, were excluded. In cases carrying multiple events within a single gene,
the allelic distribution of themutationswas determined by cloning and sequencing
PCR products obtained from cDNA and spanning both events (n5 10 clones
each).
Northern blot analysis of CREBBP and EP300 expression. Total RNA (12mg)
was extracted from exponentially growing cell lines by TRIzol (Invitrogen) and
Northern blot analysis was performed according to standard procedures, with
radiolabelled probes corresponding to a 0.9-kb fragment of the human CREBBP
cDNA (region 204–1143, GenBank accession number NM_004380.2) or a 1.2-kb
fragment of the human EP300 cDNA (region 6277–7524, GenBank accession
number NM_001429.3), and GAPDH as a control for loading. CREBBP and
EP300 expression levels were then quantitated by Phosphorimager analysis and
normalized with the GAPDH levels.
Tissue microarrays, immunohistochemistry and immunofluorescence ana-
lysis. DLBCL tissue microarrays were constructed according to standard proce-
dures and analysed by immunohistochemistry, using rabbit polyclonal antibodies
directed against the N-terminus of CREBBP (A22) or EP300 (N15) (Santa Cruz
Biotechnology). Cases were scored as positive if$20% tumour cells were stained
by the antibody. Immunofluorescence analysis of CREBBP expression in con-
ditional Crebbp/Ep300 double-knockout MEFs was performed three days after
deletion of the endogenous loci and five days after infection with HA-tagged
CREBBP retrovirus, using the CREBBP antibody (A22). The specificity of both
the A22 and the N15 antibodies had been previously validated on paraffin-
embedded cell pellets from HEK293T cells transfected with control and
CREBBP-specific short hairpin RNAs as well as by immunofluorescence staining
of Crebbp/Ep300 double-knockout MEFs (data not shown).
Protein extraction andwestern blot analysis.Whole-cell extracts were prepared
in RIPA buffer containing protease inhibitors as described18 andwere analysed by
western blotting according to standard methods, using the following primary
antibodies: anti-FLAG/M2 (Sigma), anti-HA (3F10) (Roche), anti-BCL6 (GI191E/
A8, Cell Marque), rabbit anti-acetyl lysines (Cell Signaling), anti-acetylated p53
(kind gift of W. Gu), anti-p53 (DO1), anti-CREBBP (A22), anti-EP300 (N15) (all
from Santa Cruz Biotechnology), anti-GFP (JL-8) (Clontech), anti-b-actin (clone
AC-15) and anti-b-tubulin (clone B-5-1-2) (both from Sigma). Proteins were
resolved by SDS–polyacrylamide gel electrophoresis (SDS–PAGE) in 3–8%
NuPAGETris-Acetate gels (Invitrogen), and visualized using a chemiluminescence
detection kit (Pierce) as recommended by the manufacturer.
Transient transfections/reporter gene assays. Transient transfections were per-
formed in HEK293T cells using polyethylenimine, as described46. For reporter
assays, cells were seeded on a 24-well plate and transfected using 100 ng of a
luciferase reporter construct driven by a PGL3-SV40-based backbone with five
BCL6 binding sites47, 2.5 ng of pRL-SV40 (Promega), 1 ng of BCL6-encoding
plasmid and the indicated doses of wild-type and mutant CREBBP expression
vectors. The total amount of transfected DNA was kept constant in each experi-
ment by adding pCMV–HA or pcDNA3 vector sequences to a final amount of
600 ng per well, and 3.5mg of polyethylenimine. All experiments were performed
in duplicate and luciferase activities were measured 36 h after transfection using
the Dual-Luciferase Reporter Assay System (Promega), according to the manu-
facturer’s instructions. Given the known effects of CREBBP on the SV40 pro-
moter and on other regulatory sequences, the response of the BCL6 reporter was
normalized first to that of a SV40-Renilla reporter construct, and then to the basal
activity of CREBBP on the 5X-BCL6 reporter, in the absence of BCL6. Data are
expressed as differences relative to the basal activity of the reporter construct (set
to 1) after the above-mentioned normalization.
Co-immunoprecipitation assays. To assess the interaction between CREBBP
and BCL6 or p53, HEK293T cells were co-transfected with plasmids encoding
for the two proteins, together with wild-type or mutant CREBBP-HA. Thirty-six
hours after transfection (or twenty-four hours for p53), cells were lysed in immu-
noprecipitation buffer (50mM Tris, pH 7.0, 250mM NaCl, 1mM EDTA, 1%
Triton X-100, 0.05% NP40, 10mM sodium fluoride, 0.1mM sodium orthovana-
date and protease inhibitor cocktail) (from Sigma), and the cleared lysates were
incubated overnight at 4 uC with anti-HA or anti-Flag/M2 beads (Sigma).
Immunocomplexes were eluted by incubating the beads in immunoprecipitation
buffer containing HA or 3X-Flag peptide, respectively (Sigma). A fraction of the
final eluates was resolved by SDS–PAGE and analysed by western blot.
In vitro acetyl-transferase assays. Recombinant GST–p53 and CREBBP–HA
proteins were obtained as described in detail in the Supplementary Information
and used for in vitro acteylation assays according to published protocols, with
minor modifications14,48,49. Briefly, 10–24 ng of recombinant CREBBP–HA and
100ng of GST–p53 were combined in 40ml reactions containing 50mM Tris-Cl
(pH8.0), 10% glycerol, 1mM DTT, 1mM PMSF, 0.1mM EDTA, 10mM butyric
acid (Sigma), and variable amounts of acetyl-CoA (Sigma) (2mM to 25nM). As
shown in Supplementary Fig. 6, acetyl-CoA concentrations as low as 25 nM were
sufficient to obtain efficient acetylation of the substrate by CREBBP. Reactions
were performed for 60min at 30 uC, and stopped by addition of an equal volume of
23 Laemmli buffer followed by heating for 10min at 70 uC. A fraction of the final
product was resolved by SDS–PAGE in 3–8% Tris-Acetate gradient gels
(Invitrogen) and analysed by western blotting.
Reconstitution and analysis of conditional Crebbp/Ep300 double-knockout
MEFs. The protocols for MEF isolation, cell culture and retroviral transduction,
as well as the mouse Crebbp (CBP)–HA retroviral construct used as the template
for the generation of various CREBBPmutants have been described previously50.
In this system, Cre-mediated recombination induces expression of YFP, allowing
for specific identification of the deleted cells. Crebbp flox/flox; Ep300 flox/flox; YFP1
MEFs were first infected with retroviruses encoding either wild-type or selected
CREBBP point mutants, and the endogenous Crebbp flox and Ep300 flox loci were
deleted after 48 h by infection with Cre-expressing adenovirus (Ad-Cre). The
W1502A/Y1503S HAT-dead mutation was used as negative control40. In all
experiments, transduction efficiencies were 70% or higher, as assessed by immu-
nofluorescence analysis of HA-positive cells three days after deletion of endogen-
ous Crebbp/Ep300 and five days after retroviral infection. To examine cAMP-
dependent gene expression, MEFs were cultured for 16 h in DMEM containing
0.1% FBS and treated for 90min with 10 mM forskolin 1 100mM IBMX (or
ethanol vehicle) before harvesting in TRIzol (Invitrogen); quantitative RT–PCR
assays were performed as reported50. Expression of Crebbp and Ep300 was veri-
fied by immunofluorescence analysis using rabbit polyclonal anti-CREBBP (A22)
and anti-EP300 (N20) antibodies (Santa Cruz Biotechnology). Analysis ofH3K18
acetylation was performed as described, using the anti-H3K18Ac antibody
(ab1191) (Abcam) and the HA-11 monoclonal antibody against the HA epitope
(BoehringerMannheim). Confocal images were taken using the same settings for
all mutants and mean intensity ratios for individual nuclei were collected using
SlideBook 5 software. Nuclei in which the Crebbp–HA signal was at least 2.5-fold
above background were used to calculate the ratio of the H3K18Ac mean signal
intensity to the Crebbp–HA mean signal intensity. For the growth assays shown
in Supplementary Fig. 11, Crebbp flox/flox;Ep300 flox/flox;YFP1 MEFs were infected
with CREBBP retroviruses 48 h before Ad-Cre-mediated deletion of endogenous
Crebbp and Ep300. From each reconstituted population, equivalent numbers of
YFP1 (double-knockout) MEFs were seeded at day 1 (that is, the day following
overnight Ad-Cre treatment), and the total number of YFP1 cells was calculated
on day 11 from the total cell number, based on the percentage of YFP1 cells as
assessed by flow cytometric analysis.
46. Bieber, T. & Elsasser, H. P. Preparation of a lowmolecular weight polyethylenimine
for efficient cell transfection. Biotechniques 30, 74–77,–80–81 (2001).
47. Huynh, K. D., Fischle, W., Verdin, E. & Bardwell, V. J. BCoR, a novel corepressor
involved in BCL-6 repression. Genes Dev. 14, 1810–1823 (2000).
48. Kuninger, D., Lundblad, J., Semirale, A. & Rotwein, P. A non-isotopic in vitro assay
for histone acetylation. J. Biotechnol. 131, 253–260 (2007).
49. Tang, Y., Luo, J., Zhang,W.&Gu,W.Tip60-dependentacetylationofp53modulates
the decision between cell-cycle arrest and apoptosis.Mol. Cell 24, 827–839
(2006).
50. Bedford, D. C., Kasper, L. H., Fukuyama, T. & Brindle, P. K. Target gene context
influences the transcriptional requirement for the KAT3 family of CBP and p300
histone acetyltransferases. Epigenetics 5, 9–15 (2010).
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